Laterre PF, Pickkers P, Marx G, Wittebole X, et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Med 2021;47:1284-1294.
PMID: 34605947